Imitrex (Sumatriptan)

Sumatriptan is a selective agonist of the serotonin 5‑HT1B and 5‑HT1D receptors. Activation of 5‑HT1B receptors causes constriction of intracranial blood vessels, while stimulation of 5‑HT1D receptors inhibits release of neuropeptides from trigeminal nerve endings, together interrupting the pain pathway of migraine.

The specific dose and frequency of Imitrex are determined by a qualified healthcare professional based on the individual’s medical condition, severity of migraine, and response to therapy. Prescribers may select the appropriate number of sprays per attack and any repeat dosing intervals according to clinical guidelines.

Safety data for sumatriptan in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider. Breastfeeding mothers should discuss possible exposure with their doctor.

To place an order, submit an enquiry on the Imitrex product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Imitrex (sumatriptan) belongs to the triptan class, which is generally more migraine‑specific than non‑specific analgesics such as NSAIDs. Compared with other triptans, sumatriptan has a rapid onset when administered intranasally, making it suitable for patients who prefer a non‑oral route or who experience nausea during attacks.

Imitrex nasal spray should be stored at ambient temperature below 25 °C, in its original container, protected from moisture and direct sunlight. Do not freeze the product. Keep it out of reach of children and check the expiry date before use.

Imitrex is supplied as a 20 mg nasal spray. The patient gently inserts the tip into one nostril, inhales gently, and actuates the pump to deliver the prescribed number of sprays, usually one or two per attack. The spray provides rapid absorption through the nasal mucosa, allowing quick relief.

The most serious risks include chest discomfort or tightness, which may indicate coronary vasospasm, and serotonin syndrome, a potentially life‑threatening condition that can occur when sumatriptan is combined with other serotonergic agents. Immediate medical attention is required if these symptoms appear.

Imitrex is contraindicated in patients with known coronary artery disease, uncontrolled hypertension, a history of stroke or transient ischemic attack, and in those who have previously experienced hypersensitivity to sumatriptan or any component of the nasal spray. It should also be avoided in patients taking ergot derivatives or other triptans.